Julie C Demartino

US Patent:

20020192214, Dec 19, 2002

Filed:

Aug 6, 2001

Appl. No.:

09/922895

Inventors:

Bruce Daugherty - South Orange NJ, US
Julie Demartino - Cranford NJ, US
Salvatore Siciliano - East Brunswick NJ, US
Martin Springer - Westfield NJ, US

Assignee:

Merck & Co., Inc.

International Classification:

A61K039/395
C07H021/04
C12P021/02
C12N005/06
C07K014/725

US Classification:

424/144100, 435/069100, 435/325000, 435/320100, 530/350000, 536/023500

Abstract:

The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human -chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

US Patent:

20050033024, Feb 10, 2005

Filed:

Jan 29, 2004

Appl. No.:

10/767521

Inventors:

Bruce Daugherty - South Orange NJ, US
Julie Demartino - Cranford NJ, US
Salvatore Siciliano - East Brunswick NJ, US
Martin Springer - Westfield NJ, US

International Classification:

C07K014/705
C07H021/04

US Classification:

530350000, 536023500, 435069100, 435320100, 435325000

Abstract:

The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human β-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

US Patent:

20070065849, Mar 22, 2007

Filed:

Aug 1, 2006

Appl. No.:

11/497543

Inventors:

Bruce Daugherty - South Orange NJ, US
Julie Demartino - Cranford NJ, US
Salvatore Siciliano - East Brunswick NJ, US
Martin Springer - Westfield NJ, US

International Classification:

C12Q 1/68
G01N 33/567
C07H 21/04
C12P 21/06
C07K 14/705

US Classification:

435006000, 435069100, 435320100, 435325000, 530350000, 536023500, 435007200

Abstract:

The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human β-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

US Patent:

62713477, Aug 7, 2001

Filed:

Apr 24, 1997

Appl. No.:

8/847296

Inventors:

Bruce L. Daugherty - South Orange NJ
Julie A. Demartino - Cranford NJ
Salvatore J. Siciliano - East Brunswick NJ
Martin S. Springer - Westfield NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07K 14715
C12N 510
C12N 1512
C12N 1564

US Classification:

530350

Abstract:

The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human. beta. -chemokine receptor and has been designated "CC CKR3". The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.